

Figure S1 c-Met gene expression in tumor specimens and cell lines.


Notes: (A) c-Met-positive reactivity with cancer specimens by immunohistochemistry, including 3 lung adenocarcinoma, 2 lung squamous cell carcinoma, and 4 ovarian cancer (one representative shown in Figure 1A for each group). Adjacent tissues are stained as control. Bar:100 μ m; (B) c-Met binding to A549, SKOV3, HepG2 and MDA-MB-468 cells was detected by immunofluorescence staining. Red stained for c-Met, Blue for DAPI. Bar:20 μ m; (C) c-Met binding to A549 and SKOV3 cells with BS001 and monovalent antibody, and CD3 binding to CD3⁺CD4⁺T and CD3⁺CD8⁺T with BS001 by FACS; (D) PBMC and CD3-depleted PBMC killing activity on A549 and SKOV3 mediated by BS001 at doses of 0.0001–10 μ g/mL was analyzed by LDH detection. The results were shown as mean \pm SEM; (E) Flow cytometry analyses of c-Met binding to hepa1-6 and mc38 cells with BS001; (F) PBMC killing activity on 293T cells (E:T=10:1) mediated by BS001 and the monovalent c-Met antibody. The results were shown as mean \pm SEM; (G) A549 cells were treated with the indicated concentrations of BS001 or the monovalent c-Met antibody for 8 h, and then stimulated with HGF (100 ng/mL) for 30 min. Total cell lysates were evaluated by Western blotting using indicated antibodies. GAPDH expression was used as an internal control.

Abbreviations: DAPI, 4',6-diamidino-2-phenylindole; PBMC, peripheral blood mononuclear cell; LDH, lactate dehydrogenase; HGF, hepatocyte growth factor.

1A

Tumor Patients	Lung adenocarcinoma(LUAD)	Lung squamous cell carcinoma (LUSC)	Ovarian cancer (OV)
Negative (<5%)			
+ (5-25%)	2	1	1
++ (25-50%)	1	1	1
+++ (>50%)			2
Total	3	2	4


c-Met positive tissues at 1–3+ scores







1B

c-Met high expressed cell lines

c-Met low



1C**1D****1E****1F****1G**

HGF (100ng/mL)	-	+	+	+	+	+
monovalent c-Met antibody	0.5	-	0.5	-	1.0	-
BS001 (µM)	-	-	-	0.5	-	1.0





Figure S2 BS001-mediated T-cell engagement and killing of tumor cells.

Notes: (A) FACS analyses for the PBMC before the addition to the attached tumor cells as 'initial lymphocytes'; (B) Percentages of suspended CD3⁺T and CD8⁺T cells in the supernatants after co-culture at doses of 0.01–10 μ g/mL BS001 were determined by FACS. The percentages subtracted to the initial percentage represent the attached T cells ratio shown in Figure 3C; (C) Purity verifications of microbeads-isolated subtype T cells from donor PBMC were performed by FACS. Purity: >99% for CD3⁺T and >90% for CD3⁺CD8⁺T.


Abbreviations: FACS, fluorescence activated cell sorting; PBMC, peripheral blood mononuclear cell.

2A

Lymphocyte 47.7%
 CD3+ 64.5%
 CD8+/CD3+ 52.7%

2B

A549:PBMC supernatant ratio



SKOV3:PBMC supernatant ratio







**2C**

Figure S3 BS001 inhibits tumor growth in xenograft models.

Notes: (A) Among dissected A549 tumors, CD3⁺CD8⁺T cells were detected in the 0, 4 and 10 mg/kg BS001 groups by FACS; (B,C,D) CD56-positive cells in infiltrating CD3⁺, CD25⁺, and CD8⁺T cells in the above groups were detected; the results were shown individually.(E) AST/ALT levels in serum from all groups on indicated days were detected by kit. The results were shown as mean \pm SEM. n.s represent no significant difference;

Abbreviations: FACS, fluorescence activated cell sorting; AST, aspartate transaminase; ALT, alanine transaminase.

3A**3B****3C****3D**

Vehicle	1	2	3
4mg/kg	1	2	3
10mg/kg	1	2	

3E